Johnson & Johnson reports data from Phase II prostate cancer trial
In the trial, ERLEADA plus ADT post-radical prostatectomy offered a 100% BCR-free rate at 24 months.
In the trial, ERLEADA plus ADT post-radical prostatectomy offered a 100% BCR-free rate at 24 months.
The number of pharma companies utilising AI across a medicine’s lifecycle is growing rapidly
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of new treatment...
Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
Klineo wins €2m to advance AI patient recruitment platform
Hyperfine starts enrolment in portable imaging workflow study
Acarix starts clinical workflow study for its AI-powered cardiac diagnostic
Cleerly touts new data for AI cardiovascular software